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Abstract 
The development of B cell-targeted biologics represents a major advance in the treatment of 
autoimmune rheumatic diseases. As with other immunosuppressive agents, risk of infection is 
a key clinical concern. This review summarises safety data from 15 years of experience of 
rituximab in autoimmune diseases with a particular focus on opportunistic infection and 
class-specific complications and infection risk. Rarely, cases of progressive multifocal 
leucoencephalopathy in rituximab-treated patients (5/100 000) have accumulated over time 
although no proven causal association has yet been shown. With repeat cycles of therapy, 
hypogammaglobulinaemia has been observed in a larger proportion of patients and is 
associated with increased risk of serious infections. The infection profile of the newer B cell-
targeted agent, belimumab in patients with active systemic lupus erythematosus is also 
discussed. Data from registries are needed to extend insights further and also to evaluate for 
any impact with the difference in mode of action of belimumab and infection risk in this 
population.  
(153 words)  
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Introduction 
The development of biological disease modifying anti-rheumatic drugs (bDMARDs) 
including B cell-targeted therapies represents a major advance in the treatment of 
autoimmune rheumatic diseases such as rheumatoid arthritis (RA), systemic lupus 
erythematous (SLE) and anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis 
(AAV). These therapies have been shown to provide effective therapeutic options with 
improved quality of life for patients with inadequate response to conventional synthetic 
disease modifying anti-rheumatic drugs (csDMARDs). However, the immunomodulatory 
properties of bDMARDs including rituximab have naturally raised safety concerns prompting 
careful evaluation in clinical trials and intensive post-marketing surveillance. Observations 
from these also provide insight into pathogenic basis of infectious diseases.   
The aim of this report is to review infectious risk associated with currently licensed and 
emerging B-cell therapies, the nature of reported infection and prevention strategies 
employed to minimise any risk with use of B cell-targeted therapies in autoimmune 
rheumatic diseases. In particular, we will focus on data from (open-label) long-term extension 
(LTE) studies and registry cohorts. We will conclude with our expert opinion on future 
direction of these agents and recommendation with relation to safety.  
Overview of B cell therapies currently available and emerging 
Various therapeutic strategies for B cell blockade have been investigated including B cell 
depletion, inhibition of B cell survival factors, inhibition of B cell receptor signalling, 
development of B cell tolerogens and targeting of plasma cells. These have been met with 
varying degree of success in clinical trials (1). 
Rituximab, a chimeric anti-CD20 mAb, was the first licensed treatment for B cell non-
Hodgkin’s lymphoma in 1997. In autoimmune disease, it is licensed for moderately to 
severely active patients with RA who have had an inadequate response to one or more 
Tumour Necrosis Factor-inhibitor (TNFi) and remission induction in severe, active 
granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Despite two 
negative randomised controlled trials in SLE (2, 3), rituximab is still widely used for highly 
resistant cases based on strong open label evidence (4, 5). The advantage of targeting CD20 
molecule, which is expressed on the surface of B cells is that it spares progenitor cells 
(allowing B cell regeneration) as well as long-lived plasma cells (preventing excessive 
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reduction of normal immunoglobulin levels, at least with initial therapy). However, plasma 
cell numbers may fall if B cell depletion is prolonged with multiple cycles of therapy. 
Belimumab is a fully humanised mAb that specifically binds to and neutralises the soluble 
cytokine, B cell activating factor of TNF family (BAFF), thus preventing it from binding to 
its receptors on the surface of B cells. BAFF and its homologue, APRIL are responsible for B 
cell survival, maturation and differentiation. Following the success of two randomised 
controlled trials (6, 7), Belimumab is the first and only therapy in over 50 years that has 
gained approval from the United States Food and Drug Administration (US FDA) and 
European Medicines Agency (EMA) for the treatment of active, autoantibody-positive SLE. 
Other emerging B cell-targeted therapies under evaluation include 2
nd
 generation anti-CD20 
monoclonal antibody (mAb) (where the IgG1 is humanised or fully human to reduce 
immunogenicity, but with an unmodified Fc region) such as ofatumumab and veltuzumab and 
3
rd
 generation anti-CD20 mAb (humanised and with an engineered Fc region to improve 
therapeutic performance by adapting the effector functions) such as obinutuzumab. Another 
strategy for B cell depletion and inhibition is by targeting the CD22 molecule, which is 
responsible for regulation of B cell function and is a component of the B cell activation 
complex. Epratuzumab, an anti-CD22 humanised mAb, has recently completed recruitment 
for two phase III trials in SLE for which the results will be published later in 2015. Lastly, in 
terms of BAFF/APRIL blockade, a trial of atacicept in extra-renal lupus is on-going. The 
results for atacicept in RA were negative (8) while another two in renal lupus were stopped 
prematurely due to increased therapy-associated severe infections (9, 10).  
Associated-infection and serious infection events (SIE)  
Data regarding serious infection event (SIE) from randomised controlled trials (RCTs), long-
term extension (LTE) studies and registries are summarised in Table 1. The more detailed 
data from RA are further discussed below.  
The rate of rituximab-associated SIE differs with different treatment-stages. When rituximab 
was evaluated in patients with RA and TNF-inadequate response (TNF-IR), numerically 
higher rates of SIEs were seen in the rituximab 2 x 1000mg group compared to placebo; 4.7 
versus 3.2/100 patient-years respectively in the DANCER trial (11) and 5.2 versus 3.7/100 
patient-years in the REFLEX trial(12). On the other hand, the rate of SIE was lower in the 
two rituximab dosage groups (1000 and 500 mg) compared with placebo (3.74, 4.61 and 
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6.09/100 patient-years respectively) when rituximab was evaluated in methotrexate-naive 
patients (IMAGE trial) (13). An increased risk of SIE in patients treated with rituximab 
compared with placebo was not observed in the short term from a meta-analysis of 3 RCTs 
(14). 
The 2011 Cochrane meta-analysis of use of biological therapies in RCTs in RA showed that 
of all the biologics studied, rituximab was associated with the lowest numerical odds for SIEs 
compared with control treatment (OR 0.26, 95% CI 0.03 to 2.16) albeit not statistically 
significant. When rituximab was compared indirectly with other TNFis, anakinra, abatacept 
and tocilizumab, odds for SIEs remained lower in the rituximab group and were statistically 
significant lower compared to certolizumab and anakinra (15).  
The long-term safety data of patients with RA treated and maintained with repeat cycles of 
rituximab in combination with methotrexate (MTX) have been pooled from eight RCTs and 
two LTE studies (total follow-up: 11 962 patient-years). This showed that the infection and 
SIE rates remained stable over time and with multiple courses of rituximab. Careful 
interpretation of data is needed as LTE studies sub-select patients with sustained response 
and do not include those who withdraw treatment due to intolerance. The SIE rate was 
3.94/100 patient-years in the all exposure rituximab group (3.26/100 patient-years in patients 
observed for >5 years) and was comparable with the placebo + methotrexate group (3.79/100 
patient-years). The commonest infections (>5% patients) reported in rituximab group were 
upper respiratory tract infections, nasopharyngitis, urinary tract infections, bronchitis, 
sinusitis, diarrhoea, influenza and gastroenteritis (16). This SIE rate is similar to data from 
long-term follow-up with other bDMARDs used in RA (ranging from 3.0 to 5.2/100 patient-
years) (17-19).  
The RCTs of ocrelizumab (OCR), a humanised anti-CD20 mAb in RA (20, 21) and SLE (22) 
were suspended due to increased SIE and opportunistic infections. In post-hoc analysis, 
OCR500 + MTX group demonstrated improvement in clinical response included 
radiographic outcome but this dose was associated with an increased incidence of SIEs. In 
contrast, OCR200+MTX group did not show superior efficacy compared with existing 
therapies, but was safe and well-tolerated (23). OCR was also investigated in renal lupus but 
with higher doses; 400mg and 1000mg. Despite enhanced B cell depletion was achieved in 
the OCR groups, the trial was halted due to increased SIE and opportunistic infections; some 
of which were fatal in the OCR + standard of care groups (22). 
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Risk factors for serious infection 
(i) Low immunoglobulin prior to and after therapy 
Registry data in RA show that low IgG level (<6g/L) before a cycle of rituximab was 
associated with SIE, particularly in the 3 months following rituximab infusion; 16.2% versus 
3.9% without low IgG (24). In RCTs and LTE studies in RA however, low IgM and IgG were 
exclusion criteria for trial entry. In these studies, a similar increase in SIE rate was seen 
following rituximab both before and after the development of low IgG compared with 
patients who never developed low IgG (16). This might attribute SIE to other pre-existing 
demographic or clinical risk factors rather than the low IgG itself. Careful interpretation is 
needed, as the number of patients with low IgG post-therapy was low, 3.5%. More data from 
registries are needed to assess the effect of secondary low IgG with the risk of SIE after 
repeat cycles of rituximab. 
IgM tends to decline following therapy. Levels of IgM were lower in patients receiving 
2×1000 mg rituximab versus those receiving 2×500 mg (25). In the RCTs + LTE studies, 
22.4% of patients developed low IgM (16). Low IgM prior to and post-rituximab has not 
been associated with SIE (16, 24) although this analysis may have been limited by the low 
incidence of SIE. The development of low IgA post-rituximab is uncommon (1.1%) and thus, 
does not appear to be associated with SIE (16). 
In AAV, remission induction with cyclophosphamide has led to a decline in all 
immunoglobulin classes at 6 months post-therapy and remained below the baseline levels up 
to 36 months. Following a relapse, a single cycle of rituximab further aggravated the decline 
in IgM and IgG levels (26). 
(ii) Concomitant glucocorticoid and csDMARDs 
Glucocorticoids impair phagocyte function and suppress cell-mediated immunity, and thus 
may increase the risk of infection. Registry data (AIR and BIOBADASER 2.0) shows an 
increased risk of SIE with concomitant glucocorticoid (24, 27).  A similar finding has been 
shown for TNFi in RA(28).  
The co-prescription of csDMARD appears safe. A phase II RCT showed no increase in SIE 
rates using combination methotrexate or cyclophosphamide with rituximab(29).  Data from 
the CERERRA study showed no significant difference in infection rate when rituximab was 
used either in combination with leflunomide, methotrexate or as monotherapy; rates were 
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6.2%, 6.6% and 7.4% respectively (30). Although the incidence of infection was higher in the 
rituximab and MTX group compared to rituximab monotherapy in the GISEA registry 
(33.6/100 patient-years and 9.3/100 patients-years respectively) the rate of SIE was similar 
(3.6% and 3.3% respectively) (31).  
(iii) Age and Comorbidity  
An increasing number of elderly patients, who have more co-morbidity, are diagnosed with 
autoimmune rheumatic diseases. These patients are at increased risk of SIE after rituximab 
(24, 27). Comorbidities investigated included chronic obstructive pulmonary disease 
(COPD), interstitial lung disease, renal failure, hypertension and cardiac insufficiency. 
(iv) Rituximab-associated neutropaenia 
Neutropaenia is recognised as a complication of rituximab for B cell malignancies with an 
incidence of 3-27% (32). Data in autoimmune rheumatic diseases are more limited and the 
optimal management of these patients has not been defined. Data from large cohort studies 
suggested an incidence of 2.5-3.0% in RA, increased to 20% in AAV (33, 34). In most cases 
neutropaenia recovered promptly but counts <0.5 x10
9
/L were associated with severe 
infection requiring treatment with intravenous antibiotic and granulocyte-colony stimulating 
factor (GCSF). Current data suggests retreatment with monitoring is appropriate, with 
additional caution needed only in severely neutropaenic patients (34). The mechanism of 
rituximab-associated neutropaenia remains unclear. 
Opportunistic infections 
The immunomodulatory effect of bDMARDs has raised concerns with regards to the risk of 
opportunistic infections including fungal, viral, tuberculosis and other mycobacterial 
infections. A recent meta-analysis of bDMARDs in RA trials showed that although the 
overall incidence was low, there was an increased risk of opportunistic infections with 
bDMARDs (OR 1.79; 95% CI, 1.17-2.74; I
2
=3%), resulting in 1.7 excess infections/1000 
patients treated (number needed to harm, NNH=582) compared to control (35).  Risk of 
individual agents can be linked to their targets (e.g. cytokine, T cell modulation, B cell). 
 
(i) Tuberculosis (TB) 
Two cases of pulmonary TB, both treated with anti-TB chemoprophylaxis, occurred in the 
‘All Exposure’ population in the long-term data from RCTs and LTE studies in RA (16). No 
cases of extra-pulmonary TB or multidrug-resistant TB were observed over a long period of 
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time and in other rituximab indications. This is in contrast to reactivation of latent 
tuberculosis with the use of TNFi, particularly the monoclonal antibody type. TNF-α plays a 
major role in the formation and maintenance of granulomas that confine mycobacterial 
infections by stimulating phagocytosis and enhances mycobacterial killing in concert with 
interferon gamma (IFN-γ), which cannot otherwise be eradicated by the host defence 
mechanisms (36, 37). Inhibition of TNF-α leads to loss of ability to control primary infection, 
breakdown of granulomas and release of mycobacteria and rapid progression to activation of 
latent TB. Rituximab has been administered to 7 RA patients with latent TB and 6 patients 
with TNFi-associated TB. Over the following year, no patient developed active TB or had 
QuantiFERON-TB-Gold In-Tube (QFT-GIT) conversion (38). Rare cases of non-tuberculosis 
mycobacterium; Mycobacterium avium pleuritis, and disseminated Mycobacterium kansasii 
have been reported in rituximab-treated myositis (39). Three other atypical mycobacterium 
were reported in a survey carried out in the USA and Canada (40).  
Four cases of TB (two serious pulmonary latent TB, one extra-pulmonary TB and one non-
serious latent TB) have been reported in LTE studies of belimumab in SLE. Two non-serious 
cases of non-tuberculosis mycobacterial infections have been reported (41). 
(ii) Hepatitis B and C 
Experience from oncology has demonstrated hepatitis B virus (HBV) reactivation (sometimes 
fatal) in rituximab-treated patients (15, 42). A series of case reports (n=7) have shown HBV 
reactivation following rituximab in RA patients with chronic hepatitis B infection (only 1 
received anti-viral treatment) (43). Interestingly however, a recent small prospective study 
showed no viral reactivation in any of the vaccinated group (n=4), resolved HBV infection 
(n=12) or chronic HBV infection (n=2; they received lamivudine and entecavir respectively) 
and no significant change in protective anti-HBs titres during rituximab treatment (44). 
Rituximab-related Hepatitis C virus (HCV) progression has been reported in patients with RA 
(45). A recent retrospective study was conducted in Taiwan and compared HCV progression 
in patients with RA and HCV infection treated with either TNFi or rituximab without 
concomitant anti-viral therapy. After a median follow-up of more than 2 years, no patient 
developed worsening of clinical HCV. Nevertheless, although the liver transaminases 
remained stable, viral load was significantly increased in the rituximab group compared to the 
TNFi; p=0.003 (45). This suggests a potential safety concern in patients with HCV infection, 
without anti-viral therapy.   
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There are no data to inform on exposure to belimumab in patients with a history of current 
hepatitis B or C infection. 
(iii) Herpes zoster 
Data from RCTs and LTE studies in 3194 patients with RA reported 108 cases of herpes 
zoster in 100 patients (including two cases of ophthalmic herpes zoster and five SAEs) in the 
All Exposure group compared to 13 cases in the placebo + MTX group; rates of 9/1000 
patient-years and 11.7/1000 patient-years respectively (16). This is comparable to the rate in 
the general RA population; 11.5/1000 patient-years (46). 
There were no herpes zoster cases reported in the RCTs and LTE study of belimumab in SLE 
(47), but one severe case in the Phase II trial was observed (48). 
(iv)  JC Virus reactivation (Progressive Multifocal Leucoencephalopathy) 
Progressive multifocal leucoencephalopathy (PML) is a rare, progressive, demyelinating 
disease of the central nervous system, caused by the reactivation of the JC virus. This virus is 
present in up to 80% of healthy adults, typically only causing PML in immunocompromised 
patients. Thirty-four confirmed cases of PML in the context of autoimmune rheumatic 
diseases have been reported (RA=10, SLE=17, vasculitis=4 and dermatomyositis=3). Of 
these, 14 were treated with rituximab (RA=6, SLE=5, cryoglubulinaemic vasculitis=2 and 
dermatomyositis=1) (49). This is equivalent to an incidence rate of 5/100 000 exposed patient 
which is lower than treatment for Crohn’s and multiple sclerosis with natalizumab (1/1000) 
(50) and for psoriasis with efalizumab (1/400) (51). Of the 9 outcomes known, 6 resulted in 
deaths. No definite conclusion can yet be derived on the causal link of PML in this series due 
to the small number of cases, background risk associated with disease and co-morbidity and 
concomitant immunosuppressant. 
Two cases of PML have been reported recently in patients with SLE treated with belimumab 
(52, 53) 
(v) Other Intracellular organisms (bacterial, viral or fungal) 
A small number of infections with intracellular organisms have been reported in the setting of 
rituximab therapy. Pooled data from RCTs and LTE studies in RA reported two cases of 
atypical pneumonia (no organisms isolated) and one case each of Candida septicaemia, 
pharyngeal abscess (organism unspecified), Scedosporium lung infection and Pneumocystis 
jirovecii pneumonia which equated to rate of 0.06/100 patient-years (16). The incidence of 
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Pneumocystis jirovecii pneumonia following rituximab in AAV was reported as increased to 
1.2% (54). In LUNAR trial (SLE), 3 patients had colitis, histoplasmosis, and cryptococcal 
pneumonia plus fungal sepsis, respectively (3). 
Sepsis caused by Acinetobacter baumannii was reported in the 10mg/kg belimumab group in 
the Phase III trial (7) while two other added cases of opportunistic infections were reported in 
the long term RCTs and LTE study of belimumab in SLE; coccidioidomycosis in an endemic 
area of Arizona (not-related to the drug) and another was fatal cytomegalovirus (CMV) 
pneumonia (55). 
Use in patients with human immunodeficiency virus (HIV) 
There is a limited experience on the use of rituximab in patients with autoimmune rheumatic 
disease and HIV (56). Rituximab has been widely used in the treatment of HIV-associated 
Castleman’s disease and lymphoma and seems to be well tolerated, but with a particular risk 
of reactivation of Kaposi’s sarcoma (57). 
Measures to minimise infection risk when administering rituximab 
Initiating B cell-targeted therapy 
Prior to commencing treatment, an individual therapeutic goal should be agreed between the 
patient and the treating rheumatologist (25, 58) including discussion of the risks of their 
autoimmune diseases, and benefits and risks of therapies.  
Patients should be reviewed for infection risk factors, taking into account the intensity and 
duration of immunosuppression that is likely to be needed. 
As part of pre-bDMARD screening prior to initiating a new therapy, in addition to the routine 
laboratory tests, baseline immunoglobulin levels (IgM, IgA and IgG) should be determined 
(25).  
As long-term data have not shown evidence of an increased frequency of reactivation of TB 
in autoimmune patients treated with rituximab, screening patients systematically for TB prior 
to rituximab is not necessarily recommended at the present time. A past history of TB was 
not an exclusion criterion for the BLISS-52 and 72 trials of belimumab in SLE but prior TB 
is an exclusion criterion in a new trial of belimumab in myositis [NCT02347891]. Due to 
reactivation of TB cases reported recently (41), screening for TB prior to use may be 
warranted in this disease group. 
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Patients should be screened for hepatitis B (HBsAg and anti-HBs), hepatitis B core antibody 
(anti-HBc) and hepatitis C. If antibody against anti-HBc antigen is positive, HBV DNA 
should be checked. If this viral load is negative, therapy with rituximab may be initiated with 
regular check of viral load. If the viral load is positive, then anti-viral therapy is 
recommended (see “Anti-viral therapies and monitoring for hepatitis B” section later). The 
individual risk–benefit ratio of rituximab for this group of patient with chronic HBV and/or 
chronic HCV infections should be discussed with the patient and expert 
gastroenterologist/hepatologist input is recommended in this setting. The risk of HBV or 
HCV reactivation is unknown for belimumab. 
Vaccination 
Observational studies and a RCT, showed that humoral responses to vaccination to influenza 
and pneumococcal polysaccharide (T-cell independent antigens) were impaired after 
rituximab, but not to tetanus (T-cell dependent antigen) (59-61). The low rate of infection 
among B cell-depleted patients may be explained by the preservation of cellular immunity. 
Following B cell repopulation, responses to influenza and pneumococcal polysaccharide were 
restored. For this reason, any patient considered for rituximab therapy is recommended for 
any indicated vaccines (hepatitis B for at-risk population, pneumococcus, tetanus toxoid 
every 10 years, influenza annually) either 4 weeks before the first (or next planned) course or 
at least 6 months after the last course (62).  
In a small number of patients with SLE who were treated with belimumab, they were able to 
mount a protective response to pneumococcal, tetanus or influenza vaccines (41). 
Herpes zoster vaccination (HZV) is a live, attenuated virus vaccine containing a lyophilized 
preparation of a strain of varicella-zoster virus. Previous recommendations avoid the HZV in 
patients actively receiving TNFi, as well as abatacept, rituximab and anakinra (25, 62). 
Recent safety data looks promising, reporting that, of the 110 patients receiving biologics via 
intravenous infusion (included rituximab) and 42 patients via subcutaneous injection, no 
patient in either group developed herpes zoster within the six weeks post vaccination. Only 
two patients who were vaccinated since 2012 in the infusion group developed herpes zoster at 
16 and 20 months (63). More rituximab-treated patients receiving HZV and longer-term data 
are needed before firmer treatment recommendations can be made. 
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Anti-viral therapies and monitoring for patients with Hepatitis B  
For patients with HBsAg positivity, antiviral therapy should be initiated prior to rituximab. 
The choice of anti-viral mainly depends on the duration of the scheduled therapy and on 
HBV serology status (chronic hepatitis B versus inactive carrier) (64). Patients receiving 
long-term immunosuppression i.e. >12 months) and/or suffering from chronic hepatitis B are 
usually treated with newer 2
nd
 generation anti-viral such as entecavir or tenofovir (43). 
Rituximab should not be started until the HBV DNA levels become undetectable. Thus 
frequent monitoring of HBV DNA and liver function tests (after 1 month, then every 3-6 
months) are mandatory (65, 66). 
The management of occult/resolved HBV infection with anti-HBc positivity alone remains 
unclear.  Additional risk factors should be taken into account including HBV DNA positivity, 
presence of anti-HBs (which should protect against reactivation, although this effect is 
controversial with rituximab) and the degree of immunosuppression (25, 67). For this group 
of patient, HBV DNA could be determined and then prophylactic therapy considered; if not 
undertaken, close follow-up to detect a rise in HBV DNA is recommended. 
If HBV is reactivated and HBV DNA becomes detectable, further rituximab should be 
avoided and antiviral therapy must be promptly initiated to mitigate against hepatocellular 
damage. If HBV DNA becomes positive during lamivudine therapy, switching to the 
tenofovir is recommended as cross-resistance has been reported between lamivudine and the 
other 2
nd
 generation anti-viral; entecavir. 
Monitoring after therapy 
Immunoglobulin levels should be monitored before any re-treatment particularly in those 
who demonstrate low baseline IgG levels (25). Discontinuation of rituximab should be 
considered in patients with hypogammaglobulinaemia, but this decision should take into 
account other risk factors such as age, comorbidity and glucocorticoid use, as well as the 
risks of alternatives to rituximab in patients who are B cell depleted. Monitoring is also 
warranted in patients who have had SIE to identify those who may require treatment with 
intravenous immunoglobulin replacement (IVIG). IgG level prior to and at the time of 
rituximab has been shown to be correlated with the nadir IgG post rituximab in a large cohort 
examining rituximab-associated hypogammaglobulinaemia in autoimmune rheumatic 
diseases (68). 
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The role of intravenous Immunoglobulin (IVIG) replacement 
Several studies have described the use of IVIG replacement in rituximab-treated patients who 
develop moderate to severe hypogammaglobulinaemia (IgG<5g/L) and severe infections, 
ranging from 4.2% (of 288 patients)(69) to 21% and 14 % (both consisted of <35 AAV 
patients) (26, 70). Data from a large cohort showed 6 out of 12 (50%) continued to receive 
rituximab alongside IVIG replacement therapy for maintenance of disease control. 
Replacement with IVIG reduced the incidence and severity of infections, while allowing 
recovery of IgG levels leading to cessation of IVIG replacement in two patients (after 4 and 
7.5 years of treatment). (69) 
Expert commentary 
B cell targeting appears as safe, or on occasion, safer than other classes of bDMARDs used in 
rheumatic diseases.  B cell targeted bDMARDs have important limitations in their effects on 
B cell mediated immunity. Incomplete and transient depletion of B cells and sparing of 
plasma cells may be one reason for the relative safety of rituximab. Prolonged rituximab 
therapy or more intensive B cell depleting regimens have indicated the potential for more 
significant infection risk. This is an important consideration in guiding judicious use of repeat 
rituximab cycles. Given the lifelong nature and treatment of most autoimmune diseases, we 
feel that the benefits of 6-monthly retreatment may not justify risks in many patients.  
Importantly, once hypogammaglobulinaemia is identified, it usually persists for some time, 
even if B cell depletion therapy is discontinued, thus impacting on the safety of subsequent 
bDMARDs.  Biomarkers and personalisation of therapy have shown potential in guiding the 
intensity of treatment required (56, 71, 72).   
The safety of rituximab cannot necessarily be extrapolated to all B cell targeted bDMARDs, 
as suggested by trials of OCR in SLE. Novel approaches being evaluated in clinical trials to 
more comprehensively inhibit B and plasma cell immunity, such as combination therapy with 
rituximab and belimumab or direct targeting of plasma cells with proteasome inhibitors, may 
bring additional problems(73).  
The diseases usually treated with B cell-targeted agents by rheumatologists include the most 
severe multi-system autoimmune diseases. This must be considered when interpreting 
unusual safety signals such as the PML cases that were disproportionately observed in 
patients with SLE and AAV.  Similarly, the risks of B cell targeted therapies are dependent 
on other infection risk factors (such as age and co-morbidity), and background rates of 
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opportunistic infection (as demonstrated by the geographic distribution of opportunistic 
infections in OCR trials(23)). As with many immunosuppressants, study of B cell targeted 
therapies reveals the relative risk of glucocorticoids in comparison to these more targeted 
immunosuppressants.  The benefits of glucocorticoid-sparing effects should be considered in 
the judgement of risks of B cell targeted therapies. This, as well as the immunosuppressive 
effect of disease activity itself, may help to explain why trials in SLE demonstrated lower 
rates of infection in B cell depleted patients than those with normal B cell numbers. 
As B cell depleting therapies have raised particular questions of cumulative toxicity, adequate 
surveillance must be ensured. Efficacy RCTs (and meta-analyses derived from them) are of 
limited value in identifying adverse events. LTE studies are not powered to and sub-select 
populations that tolerate therapy (74). Long-term registry data is relatively lacking but is 
needed, especially for rare and opportunistic infections.  
Finally, the future therapeutic landscape that will include an expansion in biosimilar agents 
including Rituximab biosimilars will require their own surveillance to demonstrate equivalent 
safety (75). 
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Table 1: Summary of data pertaining to serious infection, opportunistic infection and risk factors for infection of autoimmune rheumatic disease 
patients treated with either rituximab or belimumab from randomised controlled trials (RCTs), pooled data [comprising RCTs and open label 
long-term extension (LTE) studies of RCTs] and registries 
Source of Data Disease 
group 
(Number of 
Patients 
Treated with 
B cell agent) 
Duration of 
Follow-up 
Treatment 
Schedule 
Serious 
Infection Event 
(SIE)  
Opportunistic Infections Risk Factors for Infection 
RITUXIMAB 
Pooled data  (RCT+LTE) 
8 RCTs + 2 LTE 
study(16) 
RA (n=3194) 11 962 PY Rituximab 
(Either 
2×1000 mg or 
2×500 mg 
given 2 weeks 
apart in RCTs 
and for 
maintenance in 
OLEs) 
 
2428 (76%) 
were retreated 
with RTX 
3.94/100 PY 
(3.26/100 PY in 
patients 
observed >5 
years) in RTX 
Group  
 
versus 
 
3.79/100 PY in 
Placebo + MTX 
group 
Pulmonary TB reactivation (n=2) 
 
Rate of other OIs: 0.06/100 PY 
(Atypical pneumonia; n=2, Candida; 
n=1, pharyngeal abscess; n=1, 
Scedosporium lung infection; n=1, 
Pneumocystis jirovecii pneumonia; 
n=1 and JC Virus; n=1) 
 
Rate of herpes zoster in RTX group 
(9/100 PY) versus  
 
(11.7/100 PY in Placebo + MTX 
Group 
SIE rates were similar before and 
during/after low IgG, but both 
rates were significantly higher 
than in patients who never 
developed low IgG 
 
Baseline risk factors for 
development of low IgG: older, 
longer disease duration, lower 
mean CD19+count, lower mean 
IgG levels and had received more 
csDMARDs  
RCT 
RAVE(76) AAV (n=99) 18 months  Single Course 
RTX 
(375mg/m
2 
body surface 
area weekly 
for 4 weeks) 
for remission 
induction 
Rate of SIE was 
similar:   
7% and 12% at 
6 and 18 months 
in RTX 
monotherapy 
group versus 
7% and 11% in 
CyC + AZA 
None in RTX group but 3 x fatal 
infections in CyC + AZA maintenance 
Group (i) Enterococcus/Escherichia 
coli sepsis (ii) Pseudomonas 
aeruginosa sepsis and (iii) 
Pneumocystis jirovecii 
pneumonia with secondary 
Staphylococcus aureus/ Escherichia 
coli sepsis in a patient not compliant 
No risk factors identified 
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Source of Data Disease 
group 
(Number of 
Patients 
Treated with 
B cell agent) 
Duration of 
Follow-up 
Treatment 
Schedule 
Serious 
Infection Event 
(SIE)  
Opportunistic Infections Risk Factors for Infection 
maintenance 
Group 
with prophylaxis 
RITUXVAS (77) AAV (n=33) 2 years Single Course 
RTX 
(375mg/m
2
 
body surface 
area weekly 
for 4 weeks) 
for remission 
induction 
Rate of SIE 
similar: 0.25/PY 
in RTX 
monotherapy 
Group versus 
CYC + AZA 
maintenance 
Group 
2 cytomegalovirus infections reported 
in RTX Group and none in the CYC + 
AZA maintenance Group 
RTX-treated patients had higher 
VDI at baseline (median, IQR: 2 
(0-3)) compared to CYC + AZA 
maintenance (1 (0-2)) 
EXPLORER (2) SLE (n=169) 
 
78 weeks Single course 
RTX (2 x 
1000mg) 
Higher rate of 
SIE in the 
Placebo + 
csDMARDs 
group versus 
RTX + 
csDMARDs 
group; 17% and 
9.5% 
respectively 
More herpes zoster infection in 16 
RTX + Group (9.5%) versus   3 in 
Placebo + csDMARDs Group (3.4%)  
None reported 
LUNAR(3) SLE (n=72) 78 weeks Single course 
RTX (2 x 
1000mg) 
4 SIEs reported 
in each RTX + 
csDMARDs 
(16.6/100 PY) 
and Placebo 
+csDMARDs 
(19.9/100PY) 
3 OIs in RTX + csDMARDs Group: 
colitis, histoplasmosis, and 
cryptococcal pneumonia plus fungal 
sepsis, respectively versus  
1 OI in Placebo + csDMARDs Group: 
cytomegaloviral pneumonitis 
None reported 
Registry Data 
French Registry 
(AIR)(24) 
RA (n=1303) 1629 PY Most patients 
had RTX 
2x1000mg 
dose (96%) 
92 SIEs in 88 
patients (5/100 
PY) 
2 OIs: Fungal septic arthritis and 
Varicella zoster virus 
Chronic lung disease and/or 
cardiac insufficiency, 
RA-related extra-articular 
involvement and low IgG level 
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Source of Data Disease 
group 
(Number of 
Patients 
Treated with 
B cell agent) 
Duration of 
Follow-up 
Treatment 
Schedule 
Serious 
Infection Event 
(SIE)  
Opportunistic Infections Risk Factors for Infection 
 
712 (55%) 
were 
re-treated with 
RTX  
before RTX were associated with 
an increased risk of SIEs after 
RTX infusions in multivariate 
analysis 
German Registry 
(GRAID)(78) 
Total patients 
(n=370) 
including: 
 
SLE (n=85) 
AAV (n=58) 
Primary 
Sjogren’s 
(n=6) 
299 PY Most patients 
had RTX 
2x1000mg 
dose (86%) 
 
18.6% were 
retreated with 
RTX 
5.3/100 PY 5 OIs in SLE patients: Salmonella 
typhimurium (n = 1), meningococcal 
meningitis (n = 1), Listeria 
meningitis (n = 1), oesophageal 
candidiasis (n=1) and Herpes zoster 
infection (n=1) 
 
2 OIs in AAV and pemphigus patients; 
both were due to Herpes zoster 
reactivation 
There was a significant 
relationship between multiple 
repeat doses of RTX and a 
reduced rate of infections in the 
Poisson regression analysis 
Spanish Registry 
(BIOBADASER 
2.0)(27) 
Total patients 
(n=135) 
including: 
 
RA (n=75) 
Other CTD 
(n=60) 
 
However, 
Total TNFi 
treated 
patients 
studied 
(n=3166) 
245 PY RTX dose and 
number of 
cycles were 
not reported 
Higher rate of 
SIE was 
reported in RTX 
Group than 
TNFi group for 
RA (17.1 and 
7.6/100 PY 
respectively)  
 
and CTD Group 
(11.0 and 
3.1/100 PY 
respectively 
4 OIs in RTX Group: Mycobacterium 
abscessus (n=1), Candida albicans 
(n=1) and JC Virus (n=1) 
 
versus 76 OIs (predominantly 
mycobacterium infections) in the TNFi 
Group 
In Multivariate analysis, increased 
SIE was associated with use of 
rituximab  in CTD patients; many 
of which have other risk factors 
for infections included lung 
and renal problems and co-
treatments such as corticosteroids 
BELIMUMAB 
Pooled data 
 27 
Source of Data Disease 
group 
(Number of 
Patients 
Treated with 
B cell agent) 
Duration of 
Follow-up 
Treatment 
Schedule 
Serious 
Infection Event 
(SIE)  
Opportunistic Infections Risk Factors for Infection 
One RCT + LTE 
study of Belimumab 
in SLE(47) 
SLE (n=449) 1746 PY Belimumab 
(either 1mg/kg 
or 10mg/kg in 
RCT) 
 
10mg/kg dose 
in LTE 
The rate of SIE 
peaked in Year 
1 (8.3/100 PY) 
and declined in 
years 2–7 (6.0–
3.6/100 PY) 
2 OIs: coccidioidomycosis in an 
endemic area of Arizona (not-related 
to the drug) and another was fatal 
cytomegalovirus pneumonia 
None reported 
 
AAV: Anti-neutrophil cytoplasmic antibody-associated vasculitis, AZA: azathioprine, CyC: cyclophosphamide, csDMARDs: conventional disease modifying anti-rheumatic 
drugs, CTD: connective tissue diease, LTE: long term extension, MTX: methotrexate, OI: opportunistic infection, RCT: randomised controlled trial, PY: patient-year, RTX: 
rituximab, SIE: serious infection event, SLE: systemic lupus erythematosus, TB: tuberculosis and TNFi: tumour necrosis factor inhibitor, VDI: Vasculitis Damage Index 
